Commissioned and funded by: AstraZeneca GmbH, Hamburg
Non-Small Cell Lung Cancer (NSCLC)
Immune checkpoint inhibition with durvalumab according to the PACIFIC regimen has been established as the gold standard for the treatment of unresectable stage III non-small cell lung cancer (NSCLC) in the absence of progression after platinum-based chemoradiotherapy ( RCT) and tumor PD- L1 expression ≥ is 1% [1–4]. However, in daily clinical practice, randomized controlled trials are sometimes not carried out simultaneously, but rather sequentially. The PACIFIC-6 study and other studies examined the tolerability and efficacy of a sequential RCT in patients who were not suitable for a simultaneous RCT for several reasons.